Nasdaq · Healthcare
Hyperfine, Inc. (HYPR)
As-reported financials and recent SEC filings for Hyperfine, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$13.6M
Net income
$-35.6M
Net margin
—
Diluted EPS
$-0.43
ROE
-86.8%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $13.6M | $12.9M | $11.0M | $6.8M | $1.5M |
| Gross profit | $6.8M | $5.9M | $4.8M | $907,000 | $-1.2M |
| Operating income | $-37.1M | $-43.2M | $-48.1M | $-73.9M | $-64.9M |
| Net income | $-35.6M | $-40.7M | $-44.2M | $-44.2M | $-64.9M |
| Diluted EPS | $-0.43 | $-0.56 | $-0.62 | $-1.04 | $-0.92 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-04
View on EDGAR →42026-05-27
View on EDGAR →42026-05-27
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →EFFECT2026-05-21
View on EDGAR →Largest Healthcare peers
Go deeper on HYPR
Search Hyperfine, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.